Navigation Links
'EuroVacc 02' HIV Vaccine Trial Begins

This press release isn't very clear, especially when it comes to the vaccine description; be sure to read the 'note' part at the end if you want to understand what the vaccine is about.

Lausanne, Switzerland and London, United Kingdom, February 16, 2005 -- The European Vaccine Effort against HIV/AIDS today announced that a phase I clinical trial of novel investigational vaccines comprising DNA-HIV-C and NYVAC-HIV-C for the prevention of HIV infection has started in Lausanne and London in February 2005. These vaccines are based on HIV subtype C, which is prevalent in China, India and sub-Saharan Africa, and constitutes more than 50 percent of the new HIV infections worldwide.

The phase I clinical trial, with the EuroVacc Foundation as the sponsor, will evaluate the safety of DNA-HIV-C alone and of the prime-boost regimen of DNA-HIV-C+NYVAC-HIV-C, and to compare the immunogenicity of the prime-boost regimen to NYVAC-HIV-C alone in healthy volunteers at low risk of acquiring HIV infection. The study will recruit 40 healthy volunteers: 20 at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, and 20 at St Mary's Hospital, Imperial College London. All volunteers, male or female, should be between 18 and 55 yrs, HIV-negative and at low risk of infection.

The trial will carefully evaluate the safety and immunogenicity of the combination of the vaccines, in particular their ability to generate HIV-specific cell-mediated immune response to HIV, which is considered to be a key determinant of protection against infection. According to the principal clinical investigators Prof. Giuseppe Pantaleo of CHUV in Lausanne and Prof. Jonathan Weber of Imperial College London for the clinical studies, "if this study generates promising results, EuroVacc intends to further evaluate the vaccines in larger clinical trials."

Development background

The vaccine candidates for the trial - DNA-HIV-C and NYVAC-HIV-C - were develo
'"/>

Source:Imperial College London


Page: 1 2 3

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. Live Recombinant Adenovirus Vaccine Technique Explored
3. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
4. NIAID Initiates Trial of Experimental Avian Flu Vaccine
5. Study Models Impact Of Anthrax Vaccine
6. New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines
7. Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy
8. Active Vaccine Prevents Mice From Developing Prion Disease
9. New Vaccine To Be Used For First Time In Polio Outbreak Response
10. Boosting The BCG Vaccine To Beat Tuberculosis
11. Visceral Leishmaniasis: Successful Vaccine Trial In Dogs
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: EuroVacc HIV Vaccine Trial Begins

(Date:4/18/2014)... to the story of how barnyard chickens came to be, ... journal Proceedings of the National Academy of Sciences . ... 200-2300 years ago in Europe, researchers report that just a ... different from the chickens we know today. , The results ... domestic chickens -- such as their yellowish skin -- only ...
(Date:4/17/2014)... under clinical trials to treat tuberculosis could be the ... against various bacteria, fungal infections and parasites, yet evade ... chemists and collaborators. , Led by U. of I. ... ways the drug SQ109 attacks the tuberculosis bacterium, how ... from yeast to malaria and how targeting multiple ...
(Date:4/17/2014)... consumption advisories for expecting mothers are ineffective in ... organic pollutants (POPs). , The study, performed ... Toronto Scarborough PhD student Matt Binnington and Professor ... environmental contamination, a mother,s compliance with advisories, and ... exposure in her children. , Their model estimates ...
Breaking Biology News(10 mins):Ancient DNA offers clues to how barnyard chickens came to be 2Multitarget TB drug could treat other diseases, evade resistance 2Fish consumption advisories fail to cover all types of contaminants 2
... must act now if it wants to reach its Minnesota ... by 15 percent by 2015, according to a team of ... research team, which will release the new study Tuesday, July ... possible to reduce emissions by 30 percent by 2025 and ...
... completing one of the longest running experiments ever done ... University of Minnesota and the Freshwater Institute, contend that ... other jurisdictions around the world are investing millions of ... increase the problem of cultural eutrophication. The dramatic ...
... IL, Children,s Memorial Hospital of Chicago announced ... Pharmaceutical Inc. to support its Adult Phenylketonuria (PKU) Outreach ... to conduct outreach to PKU patients who are no ... to return for further education about recent developments in ...
Cached Biology News:Action needed now for Minnesota to reach goals in reducing greenhouse gas emissions by 2015 2Action needed now for Minnesota to reach goals in reducing greenhouse gas emissions by 2015 3Researchers find key to saving the world's lakes 2Children's Memorial Hospital of Chicago receives a grant from BioMarin to support adult PKU outreach 2
(Date:1/15/2014)... 15, 2014 Freeslate, Inc ., ... announced that Lupin Limited, one of India’s top five ... Protégé PharmD System for high throughput solid form ... focused on a wide range of quality, affordable generic ...
(Date:1/14/2014)... Diego, CA (PRWEB) January 14, 2014 ... on the products of cells grown under simulated embryonic ... international license agreement with Suneva Medical, Inc. for physician-dispensed ... (CCM). , This agreement is an amendment ...
(Date:1/14/2014)... Md. , Jan. 14, 2014  Organovo announced today ... the National Institutes of Health (NIH) to help scientists ... treatments to patients on a faster timeline. Organovo is ... (NCATS) and the National Eye Institute (NEI) to develop ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... and sales and operations planning ( S&OP ) service, is ... Summit , which will be held at the Hilton San ... join Kinaxis customer Elisabeth Kaszas , Director of Supply ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... , REYKJAVIK, Iceland, June 26 ... received notice from the the Nasdaq,Hearing and Listing Review Council ... to the Nasdaq Global Market effective from the,opening of trading ... under the symbol DCGN. , The ...
... TRIANGLE PARK, N.C., June 26 Syngenta Biotechnology, Inc. ... agreement with Evogene, Ltd., focusing on identifying plant genes ... will receive exclusive licensing rights to candidate genes discovered ... Soybean nematode is a soil parasite which attacks the ...
... ... Complex Localization Needs , ... China (PRWEB) June 26, 2009 -- CSOFT International Ltd., a leading provider of ... announced the upcoming launch of L10NPRO 3.0 at its 6th Annual Worldwide Operations Summit in ...
Cached Biology Technology:deCODE Reinstated to Nasdaq Global Market 2deCODE Reinstated to Nasdaq Global Market 3Syngenta and Evogene to Collaborate on Soybean Nematode Resistance 2CSOFT Announces Introduction of L10NPRO 3.0 at 6th Annual Worldwide Summit in Beijing 2CSOFT Announces Introduction of L10NPRO 3.0 at 6th Annual Worldwide Summit in Beijing 3CSOFT Announces Introduction of L10NPRO 3.0 at 6th Annual Worldwide Summit in Beijing 4CSOFT Announces Introduction of L10NPRO 3.0 at 6th Annual Worldwide Summit in Beijing 5
Anti-Human Complement Component C4c, IgY fraction (Polyclonal) (chicken IgY)...
... 15 (KLF15) KLF15 is a Cys2-His2 ... expressed in the liver, kidneys, heart, and ... Specificity: Polyclonal antibody produced in rabbits immunized ... region of human KLF15 with an internal ...
... to introduce its new line of Protein ... proteins for use in mass spectrometry, molecular ... Protein Standards are high quality purified proteins ... analyses by electrospray ionization mass spectrometry (ESI-MS). ...
... N-Dodecyl-N,N-(dimethylammonio)butyrate White crystalline solid. ... to DDMAU (Cat. No. 252005) but differing ... More efficient for the extraction of mycoplasma ... Purity: ≥98% by TLC. Soluble ...
Biology Products: